Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 1.00 |
| ▸ | CDK6 | Q00534 | 19/20 | 1.00 |
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 0.75 |
| ▸ | CDK1 | P06493 | 6/20 | 0.72 |
| ▸ | CDK7 | P50613 | 5/20 | 0.72 |
| ▸ | CDK9 | P50750 | 5/20 | 0.72 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.72 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.69 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19089152 | 1.00 | CDK4 (1.00) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089042 | 0.97 | CDK4 (1.00) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL18288884 | 0.94 | CDK4 (1.00) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL18288762 | 0.94 | CDK4 (1.00) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089037 | 0.93 | CDK4 (1.00) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089176 | 0.90 | CDK4 (0.87) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089177 | 0.90 | CDK4 (0.87) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089173 | 0.90 | CDK4 (0.87) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089262 | 0.90 | CDK4 (0.86) | CDK4CDK6CDK2CCND3CDK1 | |
| SCHEMBL19089171 | 0.90 | CDK4 (0.86) | CDK4CDK6CDK2CCND3CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | DPYD, TYMP, TYMS | CDK4 93/4885CDK6 129/4885CDK2 112/4885 |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK6, CDK4, CCNI | CDK4 2/4885CDK6 1/4885CDK2 6/4885 |
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK1, CCNI, CDK2 | CDK4 5/4885CDK6 9/4885CDK2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.